New clinical trial now open 🧪🫁
Alliance A082402 is studying if targeted post op radiation (I² PORT) can reduce recurrence in high risk #NSCLC patients after surgery while limiting side effects. Learn more https://t.co/UG6XLyzBgu. #LungCancer#ClinicalTrials#RadiationTherapy
Now recruiting! @BradMcG04 of @DanaFarber leads @ALLIANCE_org
A032201 (STRIKE) to see if adding the anti-cancer drug tivozanib to the standard treatment of immunotherapy after surgery helps patients with high-risk renal cell cancer. Learn more: https://t.co/BN81H5OBQ2 #NCI
Carbone et al. showed that mesothelioma in patients with the BAP1+/- mutation is biologically, histologically, and clinically distinct, requiring a tailored treatment approach.
Read more in this month's JTO: https://t.co/0DvkblDcnN
Does immunotherapy in #SCLC delay brain metastases? Retrospective report @LungCaJournal on 550 pts show pts treated with atezolizumab + carbo/etop longer time to intracranial progression: 24.4 vs 14.3m and if no PCI: 27.2 vs 15.2m. Improved PFS and OS.
https://t.co/sQPb3H878i
Report on NGS in squamous NSCLC @LungCaJournal from Dr. @Joshua_Reuss et al. Detected actionable genomic alterations in 22.2% of patients with squamous NSCLC and no history of smoking including #EGFR and #MET. In those with prior smoking, AGAs in 2.4%.
https://t.co/O9NQj5J4jJ
Hot off the press, Alliance CABINET! Cabozantinib in previously treated (93% had SSA, 60% had PRRT, 72% had everolimus) advanced NETs. The primary endpoint, PFS, was significantly better in the cabo arm than placebo.
@ALLIANCE_org
https://t.co/SszzXivMps
Do we need to do cardiac monitoring for all patients on Osimertinib?
Congrats to Dr Francisco Martinez, recent KPSF fellowship graduate’s poster at #wclc2024
Bottom line: >800 pts, 3700 ECHOs, only 10 Osi HF events
Higher in a fib, CHF hx pts
@KPDOR@Rayliukpsfo@LoriSakoda
EGFR mutants are not a monolithic entity. In fact EGFR mutational status is heterogeneous and EGFR mutated cancers can be Dr Jekyll or Mr Hyde #AACR24@marinagarassino
Management of pregnancy w/ 🫁ca
🚫 1st trimester
✅Dose according to actual body weight
✅Maintain dose intensity
🚫increase/decrease the dose
🚫chemotherapy @ 35-37 of gestation
✅minimum 3-week interval between the last cycle➡️delivery
🚫avoid IO in 2/3 trim
👀🫁-@matteolambe@asco #ASCO24 #lcsm